Finasteride Side Effects

Reported Finasteride side effects

Finasteride's side effect profile requires honest, detailed discussion given the unusual intersection of well-established common transient effects, rare-but-serious effects, and the disputed post-finasteride syndrome phenomenon. Trial data, post-marketing surveillance, and patient registry data each provide partial views of the full risk picture. Common sexual side effects (RCT data): Across pivotal trials of finasteride 1mg/day for hair loss, sexual side effects were reported at modestly elevated rates versus placebo. Decreased libido occurred in ~1.8% vs 1.3% (placebo), erectile dysfunction in ~1.3% vs 0.7%, ejaculation disorder (reduced ejaculate volume, delayed ejaculation) in ~1.2% vs 0.7%. At 5mg/day for BPH, rates are approximately 2-3× higher: decreased libido ~6% vs 3%, erectile dysfunction ~8% vs 4%, ejaculation disorder ~4% vs 1%. Most trial-reported sexual side effects reversed with drug discontinuation in the trial follow-up period (typically days to weeks), and many resolved with continued dosing (tolerance development). These trial-reported rates may underestimate real-world sexual side effects for several reasons: trial subjects were generally younger and healthier than real-world users; subjects with baseline sexual dysfunction were often excluded; and spontaneous reporting without specific prompting tends to underestimate subjective symptoms. Real-world surveys and patient-reported outcome studies have documented sexual side effects in 5-15% of finasteride users at various time points. Post-finasteride syndrome (PFS) — the persistent variant: Distinct from the transient sexual side effects that resolve with discontinuation, a subset of users report persistent sexual, neurologic, and psychological symptoms lasting months to years after stopping finasteride. Documented PFS-associated symptoms include: persistent loss of libido, persistent erectile dysfunction, loss of morning erections, genital sensory changes (numbness, reduced tactile sensitivity), penile shrinkage or shape changes, low mood, depression, anxiety, panic, cognitive symptoms (brain fog, memory difficulties, emotional blunting), sleep disturbance, muscle weakness or atrophy, and somatic symptoms (body composition changes, temperature dysregulation). The FDA updated Propecia labeling in April 2012 to include warnings about persistent sexual dysfunction, and subsequent updates added depression and suicidal ideation warnings. Europe, Canada, UK, and Australia have made parallel regulatory changes. Epidemiology is debated: PFS is clearly real in case series and registry data (Foundation for Post-Finasteride Syndrome patient registry has documented thousands of cases), but incidence estimates vary widely (<1% to 2-3% of users) and no prospective RCT has been specifically designed to quantify PFS rates. Individual susceptibility likely involves genetic variation in steroidogenic enzymes, age at initiation, duration of use, pre-existing mood/anxiety profile, and other factors that remain incompletely characterized. Mechanistic hypothesis involves persistent neurosteroid dysregulation (documented in Melcangi et al. studies), possibly with epigenetic or receptor-adaptation changes that don't fully resolve on discontinuation. Suicidal ideation and depression: Finasteride has been associated with depression and suicidal ideation in post-marketing surveillance, leading to FDA labeling updates including boxed warnings in some jurisdictions. Irwig 2012 documented depression and suicidal thoughts in a subset of PFS-affected men. Population-level pharmacoepidemiology studies (Welk et al. 2017 JAMA Intern Med) found modestly elevated suicide risk in older men initiating finasteride. Anyone with baseline depression, bipolar disorder, or suicidal history should have careful risk-benefit discussion before initiating; all users should be educated about mood-symptom warning signs and have a plan for prompt discontinuation and psychiatric evaluation if these occur. Gynecomastia and breast changes: Finasteride modestly increases serum estradiol (via reduced 5α-reduction of testosterone, leaving more T for aromatization). This produces breast tenderness, swelling, or gynecomastia in ~1-2% of users at 1mg/day and higher rates at 5mg/day (~2-4%). Gynecomastia is usually modest and often reverses with discontinuation but can become fibrotic and persistent with prolonged exposure, requiring surgical correction. Male breast cancer reports in finasteride users have appeared in case series and post-marketing data, though a definitive causal link remains unproven; pharmacoepidemiology is mixed. Any new breast lump, nipple discharge, or skin changes in a man on finasteride warrants immediate evaluation. PSA effects and prostate cancer screening: Finasteride suppresses serum PSA by approximately 50%, which must be accounted for in prostate cancer screening. Standard practice is to multiply the measured PSA by 2 for interpretation after ≥6 months of finasteride treatment, using the doubled value for screening algorithms. Any rise in PSA on finasteride (measured PSA increasing over baseline on-treatment level) is concerning and warrants urologic evaluation. This PSA suppression effect was a source of the initial Gleason score concern in the PCPT trial and is a real practical consideration for men using finasteride. Prostate cancer risk — contested: As discussed in clinical studies, the PCPT controversy around high-grade prostate cancer has largely been resolved in favor of finasteride's overall safety, but some practitioners remain cautious about recommending finasteride for younger men with family history of aggressive prostate cancer. This should be individually discussed. Teratogenic risk — pregnancy-category X: Finasteride causes feminization of male fetal genitalia through DHT deprivation during critical fetal developmental windows. Pregnant women should not handle crushed or broken tablets (intact tablets are coated and safe to handle). Women of reproductive potential should avoid finasteride altogether; if prescribed for post-menopausal hair loss, strict contraception should be ensured until menopause is definitively established. Semen exposure: finasteride is present in semen at low concentrations (<7 ng per ejaculate), and the theoretical exposure to a pregnant partner is below any demonstrated teratogenic threshold — condoms are not typically required for men taking finasteride with pregnant partners, though some guidelines recommend them as a precaution. Hepatic and other effects: Hepatic effects are uncommon but finasteride is CYP3A4-metabolized, and rare hepatotoxicity has been reported. Allergic reactions (rash, urticaria, angioedema) occur rarely. Testicular pain and orchialgia have been reported in post-marketing surveillance. Depression-like cognitive symptoms including reduced emotional range and concentration are commonly reported qualitatively even when not meeting clinical depression criteria. Drug interactions: Finasteride is minimally interactive in clinical practice. CYP3A4 is the primary metabolizing enzyme, but inhibition or induction rarely produces clinically significant finasteride level changes. No major interactions with most common medications have been established. Concomitant use with alpha-blockers (doxazosin, tamsulosin) for BPH is common and well-tolerated. Concomitant use with minoxidil for hair loss is standard and synergistic. Concomitant use with testosterone therapy (TRT) is possible but reduces the bodily DHT response to T normalization — some practitioners prefer to treat TRT patients without 5AR inhibitors to preserve normal DHT biology, while others continue finasteride for hair preservation during TRT.

When to continue, reduce, or stop Finasteride

Finasteride contraindications

Absolute contraindications: Pregnancy — finasteride is Pregnancy Category X (contraindicated) due to teratogenic risk. Finasteride crosses the placenta and produces feminization of male fetal external genitalia through DHT deprivation during critical developmental windows. Women who are pregnant or may become pregnant must not take finasteride and should not handle crushed or broken tablets (intact tablets are coated and safe to handle). If a partner of a man taking finasteride becomes pregnant, the low finasteride exposure from semen (<7 ng/ejaculate) is below any demonstrated teratogenic threshold and condoms are not typically mandated, though some guidelines recommend them as a precaution. Hypersensitivity to finasteride or its components — known allergic reaction to any 5α-reductase inhibitor. Active liver disease — significant hepatic impairment (Child-Pugh B-C or elevated transaminases >3× ULN) requires careful individual assessment; routine use is relatively contraindicated. Relative contraindications requiring careful discussion: Pre-existing depression, anxiety, or psychiatric history — given the association with depression and suicidal ideation in post-marketing surveillance, users with significant mood disorder history should have explicit risk-benefit discussion before initiating, close monitoring on treatment, and low threshold for discontinuation if mood symptoms emerge. Some practitioners will decline to prescribe finasteride in men with active major depressive disorder or recent suicidality. Pre-existing sexual dysfunction — men with baseline erectile dysfunction, low libido, or ejaculatory disorder may experience worsening on finasteride and may have difficulty distinguishing drug effect from baseline. Careful counseling and often preferential use of topical formulations are reasonable. Planning pregnancy in the near term — women planning pregnancy within ~1 year should not use finasteride or should discontinue with sufficient washout (4-6 weeks covers plasma clearance; semen clearance is similar). Men planning conception should be aware that finasteride does not impair fertility in most men but can affect ejaculate volume and has theoretical spermatogenesis effects at high doses. Suspected or diagnosed prostate cancer — finasteride suppresses PSA and can mask detection; in men with palpable prostate abnormalities or significantly elevated PSA, evaluation should precede initiation. In men with confirmed prostate cancer, finasteride is generally not used during active treatment without urologic oncologist direction. Family history of male breast cancer — rare but reported in finasteride users; men with strong family history should have careful breast examination at baseline and periodically. Elderly with polypharmacy — while finasteride has minimal drug interactions, elderly patients often have concurrent conditions (cardiovascular, renal, hepatic) that warrant complete review before adding another medication. Situations requiring medical consultation before use: Any psychiatric symptoms on treatment — new or worsened depression, anxiety, suicidal thoughts require immediate discontinuation and psychiatric evaluation. Do not persist through psychiatric side effects. Breast changes — new lumps, nipple discharge, skin changes, or persistent breast tenderness require prompt evaluation to rule out breast cancer and to assess gynecomastia severity. Persistent sexual dysfunction — does not resolve with brief drug holiday or dose reduction — warrants discontinuation and endocrine/urologic evaluation. Urinary retention (in men with BPH) — sudden inability to urinate despite finasteride use warrants emergency evaluation. Unexpected PSA rise on treatment — any increase in on-treatment PSA warrants urologic evaluation. Legal and regulatory notes: Finasteride is a prescription medication in essentially all countries. It is not a controlled substance and is not restricted in competitive sport (unlike DHT itself or anabolic steroids). Some military and law-enforcement entry requirements may inquire about finasteride use — disclosure is generally recommended. This is educational content only and not medical advice. Any use of finasteride for any indication warrants physician supervision, informed consent regarding the full spectrum of potential effects including post-finasteride syndrome, baseline assessment, and periodic monitoring. The decision to use or continue finasteride should involve clear-eyed assessment of individual risk tolerance, aesthetic/clinical priorities, and alternatives.

Why vendor quality drives Finasteride side-effect frequency

Research-compound communities consistently report that adverse-event frequency tracks with source quality. Three reasons: (1) impurity profiles vary by lab (residual synthesis byproducts can trigger reactions); (2) mislabeled mass means actual dose can be 50-150% of stated dose; (3) reconstitution-grade water and capping methodology affect long-term storage stability. COA-verified vendors with published HPLC data minimize all three failure modes. Check a vendor's COA record and Trust Score before you buy.

Finasteride side effects FAQ

Research-use disclaimer. All safety information on this page summarizes published research literature and community-reported reactions. It is not medical advice and not authorization for human consumption. Always consult a licensed practitioner before any compound enters a clinical context. Compounds linked from this page are sold for research-use only.
Affiliate disclosure. See our affiliate disclosure .